Literature DB >> 24742338

Characterization of host immune responses in Ebola virus infections.

Gary Wong1, Gary P Kobinger, Xiangguo Qiu.   

Abstract

Ebola causes highly lethal hemorrhagic fever in humans with no licensed countermeasures. Its virulence can be attributed to several immunoevasion mechanisms: an early inhibition of innate immunity started by the downregulation of type I interferon, epitope masking and subversion of the adaptive humoural immunity by secreting a truncated form of the viral glycoprotein. Deficiencies in specific and non-specific antiviral responses result in unrestricted viral replication and dissemination in the host, causing death typically within 10 days after the appearance of symptoms. This review summarizes the host immune response to Ebola infection, and highlights the short- and long-term immune responses crucial for protection, which holds implications for the design of future vaccines and therapeutics.

Entities:  

Keywords:  Ebola; adaptive immunity; antigenic subversion; immunoevasion; innate immunity; long-term immunity; secreted glycoprotein; type I IFN

Mesh:

Substances:

Year:  2014        PMID: 24742338     DOI: 10.1586/1744666X.2014.908705

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  44 in total

1.  Ebola control: effect of asymptomatic infection and acquired immunity.

Authors:  Steve E Bellan; Juliet R C Pulliam; Jonathan Dushoff; Lauren Ancel Meyers
Journal:  Lancet       Date:  2014-10-15       Impact factor: 79.321

2.  Robust and sustained immune activation in human Ebola virus infection.

Authors:  Judith N Mandl; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-07       Impact factor: 11.205

3.  Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.

Authors:  Edgar Davidson; Christopher Bryan; Rachel H Fong; Trevor Barnes; Jennifer M Pfaff; Manu Mabila; Joseph B Rucker; Benjamin J Doranz
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

4.  Marburg and Ravn Virus Infections Do Not Cause Observable Disease in Ferrets.

Authors:  Gary Wong; Zirui Zhang; Shihua He; Marc-Antoine de La Vega; Kevin Tierney; Geoff Soule; Kaylie Tran; Lisa Fernando; Xiangguo Qiu
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

5.  To hasten Ebola containment, mobilize survivors.

Authors:  Zena A Stein; Jack Ume Tocco; Joanne E Mantell; Raymond A Smith
Journal:  Int J Epidemiol       Date:  2014-12-09       Impact factor: 7.196

Review 6.  Ebola virus: a clear and present danger.

Authors:  Eileen M Burd
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

7.  Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia.

Authors:  Alexander Gutfraind; Lauren Ancel Meyers
Journal:  J Infect Dis       Date:  2015-01-29       Impact factor: 5.226

Review 8.  Ebola: translational science considerations.

Authors:  Francesco Chiappelli; Andre Bakhordarian; April D Thames; Angela M Du; Allison L Jan; Melissa Nahcivan; Mia T Nguyen; Nateli Sama; Ercolano Manfrini; Francesco Piva; Rafael Malagoli Rocha; Carl A Maida
Journal:  J Transl Med       Date:  2015-01-16       Impact factor: 5.531

9.  Why has the Ebola outbreak in West Africa been so challenging to control?

Authors:  T Semalulu; G Wong; G Kobinger; P Huston
Journal:  Can Commun Dis Rep       Date:  2014-08-14

Review 10.  Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.

Authors:  Vincent Madelain; Thi Huyen Tram Nguyen; Anaelle Olivo; Xavier de Lamballerie; Jérémie Guedj; Anne-Marie Taburet; France Mentré
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.